Dishman Carbogen Amcis' Subsidiary, CARBOGEN AMCIS AG, Announces Strategic Alliance with Celonic Group for Fully Integrated ADC Development and Manufacturing Platform

Dishman Carbogen Amcis Ltd. announced that its subsidiary, CARBOGEN AMCIS AG, has formed a strategic alliance with Celonic Group. This partnership aims to deliver a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution. The alliance combines Celonic’s advanced biologics capabilities with CARBOGEN AMCIS’s expertise in payload synthesis, conjugation, and sterile fill-finish. This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors. By combining their strengths, Celonic and CARBOGEN AMCIS aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch.